O28 Biosimilar use in children and young people with juvenile idiopathic arthritis in areal-world setting in the United Kingdom

Abstract

Methods: The Biologics for Children with Rheumatic diseases (BCRD) study, launched in 2010, is an ongoing prospective UK study of children with JIA starting biologic therapies other than etanercept (followed in a separate parallel study). Baseline information is collected via questionnaires completed by the treating physician or affiliated clinical research nurse. Follow-up data including disease activity measures and changes in drug therapy are collected at six months, one year and annually thereafter. Since 30/09/2015, data has been captured on three biosimilars available in the UK: infliximab (inflectra and remsima) and etanercept (benepali).